Article Details

AstraZeneca's Lynparza to dominate PARP inhibitors market with $4 billion in sales by 2027 ...

Retrieved on: 2024-04-24 13:11:58

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Lynparza to dominate PARP inhibitors market with $4 billion in sales by 2027 .... View article details on HISWAI: https://www.globaldata.com/media/pharma/astrazenecas-lynparza-dominate-parp-inhibitors-market-4-billion-sales-2027-says-globaldata/

Excerpt

Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData, comments: “Amidst this progress, AstraZeneca and Merck voluntarily withdrew ...

Article found on: www.globaldata.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up